TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy

Haematologica

Volumn 98, Issue 5, 2013, Pages

  Chiaretti, Sabina ^a   Brugnoletti, Fulvia ^a   Tavolaro, Simona ^a   Bonina, Silvia ^a   Paoloni, Francesca ^b   Marinelli, Marilisa ^a   Patten, Nancy ^c   Bonifacio, Massimiliano ^d   Kropp, Maria Grazia ^e   Sica, Simona ^f   Guarini, Anna ^a   Foà, Robin ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b GIMEMA Foundation   (Italy)

^c ROCHE MOLECULAR SYSTEMS   (United States)

^d UNIVERSITY OF VERONA   (Italy)

^e PUGLIESE CIACCIO HOSPITAL   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

Author keywords

Adult acute lymphoblastic leukemia; Response to induction chemotherapy; TP53 mutations

Indexed keywords

PROTEIN P53; ONCOPROTEIN; TP53 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; HUMAN; INDUCTION CHEMOTHERAPY; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; TP53 GENE; TREATMENT RESPONSE; GENETICS; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION; TREATMENT OUTCOME;

ADULT; HUMANS; MUTATION; ONCOGENE PROTEINS, FUSION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84877077826     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.076786     Document Type: Letter

References (15)

1. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030-1043.
2. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532-543.
3. Peller S, Rotter V. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum Mutat. 2003; 21(3):277-84.
4. Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358 (6381):15-6.
5. Fenaux P, Preudhomme C, Quiquandon I, Jonveaux P, Laï JL, Vanrumbeke M, et al. Mutations of the P53 gene in acute myeloid leukaemia. Br J Haematol. 1992;80(2):178-183.
6. Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28(29):4473-449.
7. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 1994:84(9):3148-3157.
8. Wada M, Bartram CR, Nakamura H, Hachiya M, Chen DL, Borenstein J, et al. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood. 1993;82(10): 3163-3169.
9. Kawamura M, Ohnishi H, Guo SX, Sheng XM, Minegishi M, Hanada R, et al. Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia. Leuk Res. 1999; 23(2):115-126.
10. Hof J, Krentz S, van Schewick, Körner G, Shalapour S, Rhein P, et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol. 2011;29(23):3185-3193.
11. Tang JL, Tien HF, Lin MT, Chen PJ, Chen YC. Frequent p53 mutation in relapsed acute lymphoblastic leukemia with cytogenetic instability: a longitudinal analysis. Anticancer Res. 1998;18(2B):1273-1278.
12. Zhu YM, Foroni L, McQuaker IG, Papaioannou M, Haynes A, Russell HH. Mechanisms of relapse in acute leukaemia: involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia. Br J Cancer. 1999;79(7-8):1151-1157.
13. Chiaretti S, Tavolaro S, Marinelli M, Messina M, Del Giudice I, Mauro FR, et al. Evaluation of TP53 mutations with the AmpliChip p53 Research Test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling. Genes Chromosomes Cancer. 2011;50(4):263-274.
14. Del Giudice I, Mauro FR, De Propris MS, Santangelo S, Marinelli M, Peragine N, et al. White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia. Haematologica. 2011;96(4):626-630.
15. Zhang J, Mullighan CG, Harvey RC, Wu G, Chen X, Edmonson M, et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2011;118(11):3080-3087.